JP5685254B2 - ニトロイミダゾオキサジンおよびニトロイミダゾオキサゾール・アナログならびにそれらの使用 - Google Patents

ニトロイミダゾオキサジンおよびニトロイミダゾオキサゾール・アナログならびにそれらの使用 Download PDF

Info

Publication number
JP5685254B2
JP5685254B2 JP2012523088A JP2012523088A JP5685254B2 JP 5685254 B2 JP5685254 B2 JP 5685254B2 JP 2012523088 A JP2012523088 A JP 2012523088A JP 2012523088 A JP2012523088 A JP 2012523088A JP 5685254 B2 JP5685254 B2 JP 5685254B2
Authority
JP
Japan
Prior art keywords
methyl
nitro
oxazine
imidazo
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012523088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013500997A (ja
JP2013500997A5 (enExample
Inventor
アンドリュー・エム・トンプソン
ウィリアム・アレキサンダー・デニー
エイドリアン・ブレイサー
ゼンクン・マ
Original Assignee
グローバル、アライアンス、フォア、ティービー、ドラッグ、ディベロップメント
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グローバル、アライアンス、フォア、ティービー、ドラッグ、ディベロップメント filed Critical グローバル、アライアンス、フォア、ティービー、ドラッグ、ディベロップメント
Publication of JP2013500997A publication Critical patent/JP2013500997A/ja
Publication of JP2013500997A5 publication Critical patent/JP2013500997A5/ja
Application granted granted Critical
Publication of JP5685254B2 publication Critical patent/JP5685254B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pulmonology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012523088A 2009-07-31 2010-07-30 ニトロイミダゾオキサジンおよびニトロイミダゾオキサゾール・アナログならびにそれらの使用 Expired - Fee Related JP5685254B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23042209P 2009-07-31 2009-07-31
US61/230,422 2009-07-31
PCT/US2010/043908 WO2011014776A1 (en) 2009-07-31 2010-07-30 Nitroimidazooxazine and nitroimidazooxazole analogues and their uses

Publications (3)

Publication Number Publication Date
JP2013500997A JP2013500997A (ja) 2013-01-10
JP2013500997A5 JP2013500997A5 (enExample) 2013-09-12
JP5685254B2 true JP5685254B2 (ja) 2015-03-18

Family

ID=42829983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012523088A Expired - Fee Related JP5685254B2 (ja) 2009-07-31 2010-07-30 ニトロイミダゾオキサジンおよびニトロイミダゾオキサゾール・アナログならびにそれらの使用

Country Status (13)

Country Link
US (1) US8293734B2 (enExample)
EP (1) EP2459570B1 (enExample)
JP (1) JP5685254B2 (enExample)
KR (1) KR101738868B1 (enExample)
CN (1) CN102741259B (enExample)
AU (1) AU2010278779B2 (enExample)
BR (1) BR112012002214B1 (enExample)
CA (1) CA2769263C (enExample)
ES (1) ES2530266T3 (enExample)
NZ (1) NZ598165A (enExample)
RU (1) RU2540860C2 (enExample)
WO (1) WO2011014776A1 (enExample)
ZA (1) ZA201201259B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201012209D0 (en) * 2010-05-31 2010-09-08 Ge Healthcare Ltd In vivo imaging agent
JP5916739B2 (ja) * 2011-04-15 2016-05-11 大塚製薬株式会社 ６，７−ジヒドロイミダゾ［２，１−ｂ］［１，３］オキサジン化合物
JP2015006994A (ja) * 2011-10-28 2015-01-15 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体
KR101918469B1 (ko) * 2012-06-04 2018-11-15 한국화학연구원 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
US10301294B2 (en) * 2013-03-13 2019-05-28 The Broad Institute Inc. Compounds for the treatment of tuberculosis
CN104059082B (zh) * 2013-03-21 2016-08-03 苏州迈泰生物技术有限公司 硝基咪唑杂环类化合物及其在制备治疗结核病药物中的应用
KR101564425B1 (ko) 2013-11-26 2015-10-30 한국화학연구원 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물
TWI687409B (zh) 2014-08-28 2020-03-11 日商大塚製藥股份有限公司 稠合雜環化合物
KR101682356B1 (ko) 2014-11-04 2016-12-06 한국화학연구원 이미다조 옥사진 유도체, 이의 약학적으로 허용 가능한 염 또는 이의 광학이성질체 및 이를 유효성분으로 함유하는 약제학적 조성물
WO2016119706A1 (zh) 2015-01-29 2016-08-04 南京明德新药研发股份有限公司 抗肺结核病的硝基咪唑衍生物
GB201519054D0 (en) * 2015-10-28 2015-12-09 Univ Dundee Composition
JP6905506B2 (ja) 2016-02-26 2021-07-21 大塚製薬株式会社 ピペリジン誘導体
CN108727406B (zh) 2017-03-28 2021-12-07 北京协和制药二厂 含氮杂环取代的苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
WO2020223267A1 (en) * 2019-05-01 2020-11-05 Boehringer Ingelheim International Gmbh (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
KR20240122521A (ko) 2021-12-14 2024-08-12 베링거 인겔하임 인터내셔날 게엠베하 만성 신장 질환 치료용 알도스테론 신타아제 억제제
CN114249747A (zh) * 2021-12-27 2022-03-29 苏州虞美景盛新药开发有限公司 一种用于治疗广泛耐药性结核病的硝基咪唑吡喃类药物的新合成工艺

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL41744A0 (en) 1972-03-16 1973-05-31 Ciba Geigy Ag New aryl ether derivatives,their production and their use as pesticides
CH568715A5 (enExample) 1972-03-16 1975-11-14 Ciba Geigy Ag
FR2575158B1 (fr) 1984-12-20 1987-10-02 Pf Medicament Arylalcoyloxymethyl-2 morpholines, leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
SU1271861A1 (ru) * 1985-05-07 1986-11-23 Иркутский институт органической химии СО АН СССР Способ получени 2,2-диметил-3-цианометилиденбензимидазо @ 2,1- @ -1,3-оксазолидина
US5668127A (en) * 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
US6087358A (en) 1995-06-26 2000-07-11 Pathogenesis Corporation Nitro-[2,1-b]imidazopyran compounds and antibacterial uses thereof
AR041198A1 (es) * 2002-10-11 2005-05-04 Otsuka Pharma Co Ltd Compuesto 2,3-dihidro-6-nitroimidazo[2,1-b] oxaxol, y composiciones farmaceuticas que lo contienen
CA2539335A1 (en) * 2003-10-31 2005-05-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis
JP4787529B2 (ja) 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
JP4789966B2 (ja) 2004-04-09 2011-10-12 大塚製薬株式会社 医薬組成物
EP1650211B1 (en) 2004-09-17 2011-09-14 Daiso Co., Ltd. Process for preparing imidazopyran derivatives
ATE529430T1 (de) * 2005-07-28 2011-11-15 Vertex Pharma Caspase-hemmer-propharmaka
KR20080079280A (ko) 2005-12-23 2008-08-29 노파르티스 아게 니트로이미다졸 화합물
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
WO2008008480A2 (en) 2006-07-12 2008-01-17 Cumbre Pharmaceuticals Inc. Nitroheteroaryl-containing rifamycin derivatives
NZ579431A (en) 2007-03-09 2012-04-27 Sanofi Aventis Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof
US7666864B2 (en) 2008-03-26 2010-02-23 Global Alliance For Tb Drug Development Bicyclic nitroimidazole-substituted phenyl oxazolidinones

Also Published As

Publication number Publication date
KR20120084714A (ko) 2012-07-30
RU2012107180A (ru) 2013-09-10
JP2013500997A (ja) 2013-01-10
AU2010278779A1 (en) 2012-03-08
EP2459570B1 (en) 2014-12-24
US8293734B2 (en) 2012-10-23
KR101738868B1 (ko) 2017-05-23
US20110028466A1 (en) 2011-02-03
CA2769263C (en) 2017-03-07
CA2769263A1 (en) 2011-02-03
EP2459570A1 (en) 2012-06-06
ZA201201259B (en) 2013-08-28
AU2010278779B2 (en) 2014-08-14
CN102741259A (zh) 2012-10-17
CN102741259B (zh) 2016-04-13
BR112012002214B1 (pt) 2022-01-25
WO2011014776A1 (en) 2011-02-03
RU2540860C2 (ru) 2015-02-10
NZ598165A (en) 2013-05-31
ES2530266T3 (es) 2015-02-27
BR112012002214A2 (pt) 2020-08-18

Similar Documents

Publication Publication Date Title
JP5685254B2 (ja) ニトロイミダゾオキサジンおよびニトロイミダゾオキサゾール・アナログならびにそれらの使用
CN105008375B (zh) 四氢咪唑并[1,5‑d][1,4]氧氮杂卓衍生物
KR20120044966A (ko) 1,2,4-트리아졸로〔1,5ａ〕 피리딘 유도체의 제조 및 용도
EP3207042B1 (en) Antibacterial basic biaromatic derivatives with aminoalkoxy substitution
EP2459571B1 (en) Nitroimidazooxazines and their uses in anti-tubercular therapy
CN111094267B (zh) 作为RORγ抑制剂的磺酰基取代的双环化合物
US20240246992A1 (en) Macrocyclic lrrk2 kinase inhibitors
CN117384153A (zh) 一类甲基转移酶抑制剂及其用途
JP6231107B2 (ja) マクロライド誘導体、その製造およびその治療的使用
WO2024175121A1 (zh) α，β-不饱和酰胺类化合物及其应用
WO2024153250A1 (zh) 作为usp1抑制剂的化合物
KR20250051608A (ko) Kit 저해제
US20230150985A1 (en) Inhibitors of antigen presentation by hla-dr
US9198913B2 (en) Nitroimidazooxazines and their uses in anti-tubercular therapy
US11161837B2 (en) Benzofuran derivatives for the treatment of hepatitis C
TW202543614A (zh) 噻唑基—吡唑并［１，５—ａ］吡啶化合物及其作為ＭＹＬＫ４抑制劑之用途
TW202502768A (zh) 含氮雜環衍生物
WO2025056068A1 (zh) 一类联环化合物及其制备方法和医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130730

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20131219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140909

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150113

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150116

R150 Certificate of patent or registration of utility model

Ref document number: 5685254

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees